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Abstract
Objective: To describe the likely extent of confounding in evaluating the risks of cardiovascular (CV) events and mortality in
patients using diabetes medication.
Methods: The General Practice Research Database was used to identify inception cohorts of insulin and different oral
antidiabetics. An analysis of bias and incidence of mortality, acute coronary syndrome, stroke and heart failure were
analysed in GPRD, Hospital Episode Statistics and death certificates.
Results: 206,940 patients were identified. The bias analysis showed that past thiazolidinedione users had a lower mortality
risk compared to past metformin users. There were no differences between past users of rosiglitazone and pioglitazone
(adjusted RR of 1.04; 95% CI 0.93–1.18). Current rosiglitazone users had an increased risk of death (adjusted RR 1.20; 95% CI
1.08–1.34) and of hospitalisation for heart failure (adjusted RR of 1.73; 95% CI 1.19–2.51) compared to current pioglitazone
users. Risk of mortality was increased two-fold shortly after starting rosiglitazone. Excess risk of death over 3 years with
rosiglitazone was 0.3 per 100 in those aged 50–64 years, 2.0 aged 65–74, 3.0 aged 75–84, and 7.0 aged 85+. The cause of
death with rosiglitazone was more likely to be due to a disease of the circulatory system.
Conclusions: Higher risks for death (overall and due to cardiovascular disease) and heart failure were found for rosiglitazone
compared to pioglitazone. These excess risks were largest in patients aged 65 years or older. The European regulatory
decision to suspend rosiglitazone is supported by this study.
Citation: Gallagher AM, Smeeth L, Seabroke S, Leufkens HGM, van Staa TP (2011) Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study
with the General Practice Research Database and Secondary Care Data. PLoS ONE 6(12): e28157. doi:10.1371/journal.pone.0028157
Editor: German Malaga, Universidad Peruana Cayetano Heredia, Peru
Received June 26, 2011; Accepted November 2, 2011; Published December 2, 2011
Copyright:  2011 Gallagher et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the Division of Vigilance and Risk Management of the Medicines and Healthcare products Regulatory Agency (MHRA), UK.
GPRD is owned by the Secretary of State of the UK Department of Health and operates within the Medicines and Healthcare products Regulatory Agency (MHRA).
The General Practice Research Database (GPRD) is owned by the UK Department of Health and operates within the Medicines and Healthcare products Regulatory
Agency (MHRA). GPRD has received funding from the MHRA, Wellcome Trust, Medical Research Council, NIHR Health Technology Assessment programme,
Innovative Medicine Initiative, UK Department of Health, Technology Strategy Board, Seventh Framework Programme EU, various universities, contract research
organisations and pharmaceutical companies. The department of Pharmacoepidemiology & Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences has
received unrestricted funding for pharmacoepidemiological research from GlaxoSmithKline, Novo Nordisk, the private-public funded Top Institute Pharma (www.
tipharma.nl, includes co-funding from universities, government, and industry), the Dutch Medicines Evaluation Board, and the Dutch Ministry of Health. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Tjeerd.vanstaa@GPRD.com
Introduction
The thiazolidinediones - rosiglitazone and pioglitazone - have
been widely used for the treatment of type 2 diabetes mellitus.
However, signals concerning the cardiovascular safety have been
emerging over the last few years. An increased risk of myocardial
infarction (MI), with no increases in mortality was found for
rosiglitazone in a meta-analysis of randomised controlled trials
(RCTs) [1,2]. Pioglitazone was reported to have a statistically
significant lower risk in a composite endpoint of death, MI and
stroke from findings of another meta-analysis [3]. These reports
were supported by a FDA meta-analysis of RCTs, which found
that the risk of all-cause and cardiovascular mortality and MI
tended to be lower with pioglitazone and higher with rosiglitazone
(although most results did not reach statistical significance) [4].
This analysis also highlighted that the risk of congestive heart
failure was increased with both drugs [4]. Another study also noted
the increase in numbers of congestive heart failure with both
thiazolidinediones [5]. Limitations of these meta-analyses are the
low number of events and the pooling of studies with varying
designs and study populations. Furthermore, the populations using
the drugs and exposure characteristics in actual clinical practice
may be different from those enrolled in RCTs [6].
A large number of observational studies have also evaluated the
cardiovascular safety of rosiglitazone or pioglitazone but the
quality of these studies varied considerably [7–32]. An unpub-
lished assessment by the UK medicines and medical devices
regulatory authority of 24 observational studies noted substantial
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limitations in most studies, including limited statistical power, short
durations of follow-up or study populations with lack of long-term
continuity of data collection. Also, observational studies relied on
the power of statistical adjustment to deal with confounding.
Confounding (which is a challenge in any observational study) may
be even more challenging in studies of diabetes, since drug
exposure is defined by diabetes severity, making it very difficult to
separate the effect of disease severity from treatment.
There has been an ongoing European regulatory review of the
cardiovascular safety of thiazolidinediones and a study was
commissioned by the UK Medicines and Healthcare products
Regulatory Agency (MHRA) (this was done prior to the
subsequent suspension of rosiglitazone in Europe). The first
objective of the present study was to describe the likely extent of
confounding in evaluating the risks of cardiovascular events and
mortality in patients using diabetes medication. Where confound-
ing effects could be adequately controlled, the second objective
was to compare the risks of cardiovascular events and mortality
between different types of diabetes medication, including rosigli-
tazone and pioglitazone.
Methods
Data source
This study used data from the General Practice Research
Database (GPRD) in the United Kingdom. GPRD comprises the
computerised medical records maintained by general practitioners
(GPs). GPs play a key role in the UK health care system, as they
are responsible for primary health care and specialist referrals.
Patients are affiliated with a practice, which centralises the medical
information from the GPs, specialist referrals and hospitalisations.
The data recorded in the GPRD since 1987 include demographic
information, prescription details, clinical events, preventive care
provided, specialist referrals, hospital admissions and their major
outcomes [33]. A recent review of all validation studies found that
medical data in GPRD were generally of high quality [34].
Patients in about 40% of GPRD have now been linked
individually and anonymously to the national registry of hospital
admission (Hospital Episode Statistics [HES]) and to the death
certificates (as collected by the Office of National Statistics). For
each hospitalised patient, the hospital charts are reviewed, dates of
admission and discharge and main diagnoses are extracted, coded
by coding staff and collated nationally into HES. The death
certificates list the date and causes of death. HES data were
available from April 1997 and death certificates from January
2001 for about 40% of GPRD practices. The data from HES and
GPRD were recorded and collected independently from each
other.
Study population
The exposed study cohort consisted of adults aged 40 years and
older with a prescription for insulin or oral antidiabetic drugs
(OAD) at least one year after start of data collection. Patients with
a record of type I diabetes were excluded. The index date was the
first prescription for insulin or OAD one year after start of GPRD
data collection (the prescribing prior to the index date was not
considered in the creation of this prevalent user cohort). The
period of follow-up was from the index date up to the date of
censoring (i.e., transfer out of the practice, last collection from the
practice, or death). Each exposed patient was matched by age
(within 5 years), sex and practice to one control patient, with the
index date of the control being the same as that of the exposed
patient. Within this overall exposed cohort, we identified inception
cohorts for each class of diabetes medication (a patient was
included in an inception cohort if they received first-ever
prescription for a class of diabetes medication at least one year
after start of GPRD data collection). The medications of interest in
this study were thiazolidinediones, insulins, metformin and
sulphonylureas. Furthermore, we also created two inception
cohorts separately for pioglitazone and rosiglitazone. Patients
prescribed multi-constituent preparations were included in
multiple classes of diabetes medication.
In order to prevent immortal time bias and incorrect exclusion
of patients based on events that occur after the index date, patients
could belong to multiple inception cohorts. In comparisons
between different diabetes medications, patients were censored
at the start of treatment with the medication of the reference
group. The exposure to each diabetes medication was classified in
a time-dependent manner, dividing the period of follow-up into
periods of current, recent and past exposure. The period of current
exposure was defined as the period from the date of a prescription
up to 3 month after the date of the prescription. Recent use was
the period of time from 3 to 12 months after the most recent
prescription and past use was the time from 12 months after.
Patients could move between exposure categories over time.
Outcomes of interest
The following incident outcomes were measured: death due to
any cause (as recorded in GPRD or on death certificates), cause
of death (death certificates), acute coronary syndrome (ACS)
(recorded in GPRD or HES), stroke (GPRD or HES) and heart
failure (GPRD or HES). Analyses requiring the HES or ONS data
were restricted to patients from practices participating in the
linkage and to those with data during the HES/ONS data
collection period. Given the different coding dictionaries used by
the various datasets and different methods for data collection,
outcomes from each source were analysed separately.
Statistical analyses
Four sets of analyses were conducted. The first set of analyses
evaluated the possible extent of bias in the comparisons between
different diabetes medications and whether statistical adjustment
with risk factors would sufficiently address any confounding. In
this analysis, the incidence of various outcomes was compared
between past exposure for each of the diabetes medications and
matched control patients. Poisson regression was used to estimate
relative rates (RRs). These models also included age, sex, calendar
year, small-area socioeconomic status (for linked practices),
smoking status, use of alcohol, body mass index, medical history
ever before of coronary heart disease, coronary revascularisation,
hyperlipidaemia, hypertension, peripheral vascular disease, renal
impairment and stable angina and prescribing in the 6 months
before of angiotensin II receptor blockers, antiplatelets, beta
blockers, calcium channel blockers, diuretics, nitrates, NSAIDs or
aspirin and statins. In addition, the models included use of current
use of the various classes of diabetes medication. Missing values for
alcohol use, smoking status and body mass index were included as
separate categories in the regression analyses. This bias analysis
explored whether statistical adjustment substantially reduced the
point estimates of RRs towards one. If the adjusted RRs would
remain elevated, this could either indicate residual confounding
(i.e., effects of the underlying disease) or persistent adverse effects
after treatment discontinuation.
The second set of analyses concerned a comparison of the rates
of outcomes during current use of different diabetes medications.
These analyses were restricted to the types of diabetes medications
that did not have major differences in risk during past use (as
observed in the previous set of analyses). These analyses were
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stratified by age, co-prescribing of insulin and calendar time
(before and after 2007; in October 2007 additional warnings for
cardiovascular disease with rosiglitazone were communicated by
the UK regulatory authority.
The third set of analyses described the pattern of risks over
duration of treatment. The follow-up period of current exposure
was divided into 100 periods and the absolute risk was estimated
within each small period. These estimates were then smoothed
using the method proposed by Ramlau-Hansen [35]. This analysis
of hazard rates displays visually the observed (crude) risks over
duration of current exposure to a diabetes medication.
The last set of analyses estimated the cumulative incidence over
time with current use of various medications for diabetes. Kaplan-
Meier life-tables were estimated. These life-tables describe the
absolute incidence over time, accounting for loss to follow-up
while not adjusting for any risk factors.
Results
Demographics
The overall study population included 206,940 patients pre-
scribed insulin or OAD and the same number of controls without
diabetes. Table 1 shows the baseline characteristics of the inception
cohorts of metformin, sulphonylureas, rosiglitazone, pioglitazone
and insulins. As expected, there were differences in risk factors
between metformin, sulphonylureas and insulin (metformin was
more often the first diabetes treatment while insulin users had more
frequent history of use of other diabetes treatments). There were no
major differences at baseline for most characteristics between
rosiglitazone and pioglitazone, except for prescribing over calendar
time and higher prior use of statins among pioglitazone users (this
was found to be related to secular changes in statin prescribing). The
number of patients starting rosiglitazone dropped substantially after
Table 1. Baseline characteristics at inception date of metformin, sulphonylureas, rosiglitazone, pioglitazone and insulin.
Characteristic
Metformin
N=121,637 N (%)
Sulphonylureas
N=76,863 N (%)
Rosiglitazone
N=22,636 N (%)
Pioglitazone
N=18,953 N (%)
Insulin N=26,458
N (%)
Mean Age, years (sd) 64 (12) 66 (12) 63 (11) 64 (11) 66 (11)
Median Age, years (IQR) 64 (55–73) 66 (57–74) 63 (55–72) 64 (56–72) 66 (57–74)
Sex: Female 53,649 (44.1%) 33,982 (44.2%) 9,939 (43.9%) 7,939 (41.9%) 11,678 (44.1%)
Male 67,988 (55.9%) 42,881 (55.8%) 12,697 (56.1%) 11,014 (58.1%) 14,780 (55.9%)
Mean Follow-up, years (sd) 4 (3) 5 (4) 5 (2) 3 (2) 4 (3)
Mean BMI (sd) 31 (6) 30 (6) 31 (6) 32 (6) 30 (6)
Mean HbA1c,% (sd) 8.8 (1.8) 9.0 (1.8) 8.9 (1.5) 8.7 (1.5) 9.8 (1.8)
Smoking Status Non Smoker 48,487 (39.9%) 30,748 (40.0%) 8,736 (38.6%) 6,799 (35.9%) 9,941 (37.6%)
Ex Smoker 46,146 (37.9%) 26,809 (34.9%) 9,556 (42.2%) 8,989 (47.4%) 10,421 (39.4%)
Smoker 22,330 (18.4%) 13,760 (17.9%) 3,950 (17.5%) 3,031 (16.0%) 4,909 (18.6%)
Unknown 4,674 (3.8%) 5,546 (7.2%) 394 (1.7%) 134 (0.7%) 1,187 (4.5%)
Hospitalisation in the year before 11,391 (22.6%) 8,658 (27.4%) 1,979 (20.5%) 1,747 (22.0%) 5,112 (43.8%)
Number of diabetes medication
classes ever before: 0
89,922 (73.9%) 36,260 (47.2%) 645 (2.8%) 389 (2.1%) 2,917 (11.0%)
1 29,067 (23.9%) 34,393 (44.7%) 8,628 (38.1%) 4,595 (24.2%) 3,081 (11.6%)
2 2,371 (1.9%) 5,703 (7.4%) 11,302 (49.9%) 8,747 (46.2%) 11,024 (41.7%)
3 248 (0.2%) 459 (0.6%) 1,838 (8.1%) 4,357 (23.0%) 7,683 (29.0%)
4 29 (0.0%) 45 (0.1%) 207 (0.9%) 746 (3.9%) 1,563 (5.9%)
5+ 0 (0.0%) 3 (0.0%) 16 (0.1%) 119 (0.6%) 190 (0.7%)
History of ACS 13,132 (10.8%) 9,017 (11.7%) 2,378 (10.5%) 1,989 (10.5%) 5,056 (19.1%)
Stroke 8,031 (6.6%) 5,944 (7.7%) 1,349 (6.0%) 1,172 (6.2%) 2,534 (9.6%)
Heart failure 5,294 (4.4%) 5,268 (6.9%) 831 (3.7%) 550 (2.9%) 2,765 (10.5%)
Stable angina 15,900 (13.1%) 11,009 (14.3%) 3,081 (13.6%) 2,511 (13.2%) 4,903 (18.5%)
Hyperlipidaemia 11,488 (9.4%) 6,685 (8.7%) 2,791 (12.3%) 2,572 (13.6%) 2,925 (11.1%)
Hypertension 84,968 (69.9%) 53,462 (69.6%) 17,618 (77.8%) 15,424 (81.4%) 20,470 (77.4%)
Recent prescribing of Nitrates 11,664 (9.6%) 8,540 (11.1%) 2,158 (9.5%) 1,653 (8.7%) 4,308 (16.3%)
Beta blockers 29,206 (24.0%) 17,938 (23.3%) 5,636 (24.9%) 4,623 (24.4%) 7,065 (26.7%)
Calcium channel blockers 29,382 (24.2%) 18,532 (24.1%) 6,183 (27.3%) 5,681 (30.0%) 7,656 (28.9%)
Diuretics 41,234 (33.9%) 27,929 (36.3%) 7,651 (33.8%) 6,645 (35.1%) 10,917 (41.3%)
Antiplatelets 43,468 (35.7%) 27,971 (36.4%) 10,441 (46.1%) 10,049 (53.0%) 12,669 (47.9%)
ACE inhibitors/angiotensin II
receptor blockers
51,946 (42.7%) 31,870 (41.5%) 13,132 (58.0%) 12,371 (65.3%) 14,595 (55.2%)
Statins or fibrates 61,239 (50.3%) 35,295 (45.9%) 15,271 (67.5%) 14,934 (78.8%) 15,502 (58.6%)
NSAIDs 54,420 (44.7%) 34,424 (44.8%) 12,111 (53.5%) 11,071 (58.4%) 14,010 (53.0%)
doi:10.1371/journal.pone.0028157.t001
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2007 (2006, N=4583; 2007, N=2612; 2008, N=474; 2009,
N=278). The use of pioglitazone changed differently (2006,
N=1543; 2007, N=2815; 2008, N=4660; 2009, N=3177).
Bias analyses
Table 2 shows the results of the bias analyses. The statistical
comparison showed major differences, as expected, in the risks of
cardiovascular outcomes and death between the overall exposed
cohort and control cohort. Statistical adjustment did reduce the
RRs for the cardiovascular outcomes, although statistically
significant differences remained. For mortality, statistical adjust-
ment increased the RRs with higher risks in the exposed cohort
(indicating that diabetes treatments are less likely to be given to
patients at imminent risk of death). In the analysis of past
exposure, it was found that patients who had discontinued insulin
had a higher risk of death compared to past users of metformin.
Past thiazolidinediones users had a lower risk of death. The RRs
were comparable in past rosiglitazone users compared to past
pioglitazone users (adjusted RRs of 1.04 [95% 0.93–1.18], 1.11
[95% CI 0.86–1.43], 0.76 [95% CI 0.56–1.03] and 0.95 [95% CI
0.74–1.23 for, respectively, death, ACS, stroke and heart failure in
GPRD). These results suggest that comparisons of different classes
of diabetes medications are likely to be prone to substantial
confounding, while the within class comparison of rosiglitazone
versus pioglitazone is less prone to selection bias and confounding.
Comparison of rates of outcomes with current diabetic
medications
As shown in Table 3, current rosiglitazone users had an
increased risk of death compared to current pioglitazone users
(adjusted RR 1.20 [95% CI 1.08–1.34]). The rates of ACS and
stroke were comparable between rosiglitazone and pioglitazone.
Hospital admission for congestive heart failure was increased with
rosiglitazone (adjusted RR of 1.73 [95% CI 1.19–2.51]) while
heart failure diagnosed or treated by a GP was statistically
comparable between the two types of thiazolidinediones (adjusted
RR of 1.14 [95% CI 0.97–1.34]). Table 4 shows the analyses
stratified by age, co-prescribing of insulin and calendar time. The
RRs comparing current rosiglitazone to pioglitazone users did not
vary substantially.
Table 5 shows the mortality rates and primary cause of death in
current rosiglitazone and pioglitazone users. Rosiglitazone users
were more likely to die due to a disease of the circulatory system
compared to pioglitazone users (although these findings did not
reach statistical significance).
Patterns of Risks
Figure 1 shows the smoothed RRs over duration of treatment in
rosiglitazone users compared to pioglitazone users. It was found
that the risk of mortality was increased about two-fold shortly
following the start of rosiglitazone treatment (compared to
pioglitazone) and then remained elevated (although at a much
lower level) with longer treatment duration.
Cumulative incidence over time
An additional seven patients (per 100 patients over 3 years) died
during rosiglitazone treatment compared to pioglitazone in those
aged 85 years or older (Table 6). The excess risks were
progressively smaller in younger patients (there was an excess risk
of death of 0.3 per 100 in those aged 65 years or younger).
Table 2. Rates of outcomes (in GPRD) during past exposure compared to matched control cohort or to past metformin exposure.
Comparison with control cohort without diabetes Comparison with past exposure of metformin
Outcome Drug Class
Age, sex, calendar year
adjusted RR (95%CI)
Fully adjusted RR
(95%CI)
Age, sex, calendar year
adjusted RR (95%CI)
Fully adjusted RR
(95%CI)
Death Insulin 2.40 (2.20–2.61) 2.84 (2.60–3.11) 1.38 (1.26–1.50) 1.24 (1.12–1.37)
Sulphonylureas 1.77 (1.72–1.82) 2.18 (2.11–2.26) 0.96 (0.89–1.03) 0.97 (0.90–1.04)
Thiazolidinediones 1.77 (1.66–1.88) 3.04 (2.77–3.33) 0.81 (0.76–0.85) 0.84 (0.79–0.89)
Metformin 2.01 (1.96–2.07) 2.23 (2.15–2.31) Reference Reference
Controls Reference Reference N/A N/A
ACS Insulin 2.00 (1.54–2.61) 1.68 (1.27–2.21) 1.00 (0.76–1.32) 1.04 (0.79–1.37)
Sulphonylureas 2.38 (2.23–2.54) 1.63 (1.51–1.77) 1.23 (1.03–1.48) 1.29 (1.08–1.55)
Thiazolidinediones 2.47 (2.17–2.81) 1.61 (1.31–1.97) 1.03 (0.91–.118) 1.05 (0.92–1.20)
Metformin 2.48 (2.32–2.67) 1.55 (1.42–1.68) Reference Reference
Controls Reference Reference N/A N/A
Stroke Insulin 1.91 (1.45–2.52) 1.91 (1.43–2.56) 0.99 (0.75–1.32) 0.95 (0.71–1.26)
Sulphonylureas 1.82 (1.68–1.97) 1.60 (1.45–1.76) 1.01 (0.82–1.25) 1.04 (0.85–1.29)
Thiazolidinediones 1.90 (1.61–2.25) 1.89 (1.46–2.45) 0.91 (0.77–1.07) 0.92 (0.79–1.09)
Metformin 2.05 (1.89–2.22) 1.72 (1.56–1.89) Reference Reference
Controls Reference Reference N/A N/A
Congestive
Heart Failure
Insulin 2.23 (1.74–2.87) 1.62 (1.25–2.10) 0.94 (0.73–1.22) 0.94 (0.73–1.22)
Sulphonylureas 2.45 (2.30–2.62) 1.42 (1.31–1.54) 1.20 (0.99–1.44) 1.34 (1.12–1.62)
Thiazolidinediones 3.23 (2.80–3.72) 1.75 (1.41–2.17) 1.12 (0.98–1.28) 1.13 (0.99–1.29)
Metformin 2.97 (2.77–3.19) 1.50 (1.38–1.63) Reference Reference
Controls Reference Reference N/A N/A
doi:10.1371/journal.pone.0028157.t002
Thiazolidinediones and Cardiovascular Risk
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28157
Table 3. Rates of outcomes during current exposure of pioglitazone and rosiglitazone.
Outcome Class
Number
of cases
Incidence
rate&
Age, sex, calendar year
adjusted RR(95% CI) Fully adjusted RR(95%CI)
Death (GPRD) Pioglitazone 487 1.7 Reference Reference
Rosiglitazone 1274 2.0 1.15 (1.04–1.28) 1.20 (1.08–1.34)
Death (ONS) Pioglitazone 145 1.6 Reference Reference
Rosiglitazone 469 1.9 1.09 (0.90–1.32) 1.07 (0.89–1.29)
ACS (GPRD) Pioglitazone 219 0.9 Reference Reference
Rosiglitazone 510 0.9 0.99 (0.84–1.16) 1.03 (0.87–1.21)
ACS (HES) Pioglitazone 67 0.8 Reference Reference
Rosiglitazone 203 0.9 1.04 (0.79–1.37) 1.02 (0.77–1.35)
Stroke (GPRD) Pioglitazone 108 0.4 Reference Reference
Rosiglitazone 254 0.4 1.00 (0.80–1.26) 1.05 (0.83–1.32)
Stroke (HES) Pioglitazone 31 0.4 Reference Reference
Rosiglitazone 105 0.4 1.16 (0.77–1.74) 1.12 (0.75–1.68)
Congestive Heart Failure (GPRD) Pioglitazone 208 0.7 Reference Reference
Rosiglitazone 534 0.9 1.08 (0.92–1.27) 1.14 (0.97–1.34)
Congestive Heart Failure (HES) Pioglitazone 34 0.4 Reference Reference
Rosiglitazone 172 0.7 1.73 (1.19–2.50) 1.73 (1.19–2.51)
&Number of cases per 100 person years.
doi:10.1371/journal.pone.0028157.t003
Table 4. Rates of outcomes (in GPRD) during current exposure of rosiglitazone compared to pioglitazone stratified by age, co-
prescribing of insulin and calendar time.
Outcome Stratification Age, sex, calendar year adjusted RR (95%CI) Fully adjusted RR (95%CI)
Death Age ,65 1.08 (0.82–1.41) 1.14 (0.87–1.49)
$65 1.17 (1.04–1.31) 1.22 (1.09–1.37)
ACS Age ,65 0.79 (0.61–1.03) 0.82 (0.64–1.07)
$65 1.12 (0.92–1.38) 1.17 (0.95–1.43)
Stroke Age ,65 0.84 (0.52–1.36) 0.90 (0.56–1.46)
$65 1.05 (0.81–1.36) 1.09 (0.84–1.41)
Congestive Heart Failure Age ,65 0.90 (0.61–1.34) 0.95 (0.64–1.42)
$65 1.12 (0.94–1.34) 1.19 (0.99–1.42)
Death Co-prescribing insulin: no 1.16 (1.05–1.30) 1.22 (1.09–1.35)
yes 1.12 (0.63–1.97) 1.20 (0.68–2.13)
ACS Co-prescribing insulin: no 0.98 (0.83–1.15) 1.00 (0.85–1.18)
yes 1.70 (0.71–4.08) 1.83 (0.76–4.42)
Stroke Co-prescribing insulin: no 0.98 (0.78–1.23) 1.02 (0.81–1.29)
yes 2.54 (0.49–13.16) 2.66 (0.51–13.84)
Congestive Heart Failure Co-prescribing insulin: no 1.11 (0.94–1.31) 1.16 (0.98–1.37)
yes 0.73 (0.31–1.75) 0.80 (0.33–1.91)
Death ,2007 (calendar year) 1.15 (0.98–1.35) 1.20 (1.03–1.41)
$2007 1.13 (0.98–1.30) 1.19 (1.03–1.37)
ACS ,2007 1.04 (0.83–1.30) 1.06 (0.84–1.33)
$2007 0.90 (0.71–1.13) 0.94 (0.75–1.19)
Stroke ,2007 1.33 (0.94–1.87) 1.40 (0.99–1.98)
$2007 0.74 (0.54–1.02) 0.76 (0.55–1.06)
Congestive Heart Failure ,2007 1.04 (0.83–1.29) 1.10 (0.88–1.37)
$2007 1.13 (0.89–1.43) 1.20 (0.94–1.53)
doi:10.1371/journal.pone.0028157.t004
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Appendix S1 lists the cumulative incidence of ACS, stroke and
heart failure.
Discussion
This study found that there was a substantive heterogeneity
between the populations using different classes of various diabetes
medications and that statistical adjustment with the measured risk
factors only partially eliminated this bias. Comparable populations
used rosiglitazone and pioglitazone. Higher risks for death (overall
and due to cardiovascular disease) and heart failure were found for
rosiglitazone compared to pioglitazone, with the risks of death
highest shortly after starting treatment and disappearing after
discontinuation of rosiglitazone.
Several studies have evaluated the cardiovascular safety of
different classes of diabetes medications [7–32]. As an example,
Tzoulaki and collaegues concluded that sulphonylureas had an
unfavourable risk profile compared with metformin [25]. All of
these studies relied on regression analysis to deal with confounding
but none tested whether this statistical approach indeed minimised
confounding. Although not routinely conducted, the formal
analysis of bias has been recommended to be a critical part of
an analysis [36]. We used two approaches for this bias analysis
(one evaluating diabetes patients to controls and one comparing
past exposure of different drugs). Both these analyses suggested
that statistical adjustment only partially removed confounding due
to the underlying disease. But there may be alternative
explanations of these findings, namely that most diabetes drugs
have cardiovascular side-effects or that various diabetes drugs have
persistent effects (increasing the risks during past exposure).
Although we can not exclude with certainty these alternative
explanations, the presence of residual confounding due to
underlying disease seems most likely as in diabetes mellitus drug
exposure is defined by diabetes severity. As drug exposure is
defined by diabetes severity, epidemiological comparisons between
different classes of diabetes medications should not simply rely on
statistical adjustment with a few risk factors but should evaluate the
extent of bias in these comparisons.
Rosiglitazone and pioglitazone appeared to be used in the UK
by comparable populations, as indicated by the lack of differences
in cardiovascular risks during past exposure and general similarity
in baseline risk factors. Our findings of higher risks with
rosiglitazone could be explained by a relatively higher level of
toxicity or by a lower level of benefit with rosiglitazone. Given the
Table 5. Mortality rates and primary cause of death in rosiglitazone and pioglitazone current users.
Rosiglitazone Pioglitazone
Primary cause of death (ICD 10 codes)
Number
of cases
Incidence
rate&
Number
of cases
Incidence
rate&
Age, sex, calendar year
adjusted RR (95% CI)
All cause 469 1.9 145 1.63 1.09 (0.90–1.32)
A00–B99: Certain infectious and parasitic diseases 7 0.03 7 0.08 0.30 (0.10–0.87)
C00–D89: Neoplasms/Diseases of the blood and
blood forming organs
106 0.43 38 0.43 0.95 (0.65–1.38)
E00–E90: Endocrine, nutritional and metabolic disorders 25 0.1 14 0.16 0.56 (0.29–1.09)
F00–F99: Mental and behavioural disorders 3 0.01 1 0.01 1.30 (0.13–12.77)
G00–G99: Diseases of the nervous system 1 0 3 0.03 0.11 (0.01–1.05)
I00–I99: Diseases of the circulatory system 223 0.9 56 0.63 1.34 (1.00–1.80)
I20–I25: Ischemic heart disease 176 0.71 47 0.53 1.26 (0.91–1.75)
I50: Heart failure 88 0.36 21 0.24 1.36 (0.84–2.19)
J00–J99: Diseases of the respiratory system 55 0.22 10 0.11 1.91 (0.97–3.77)
K00–K93: Diseases of the digestive system 25 0.1 11 0.12 0.78 (0.38–1.59)
L00–L99: Diseases of the skin and subcutaneous tissue 4 0.02 0 0
M00–M99: Diseases of the musculoskeletal system
and connective tissue
1 0 1 0.01 0.30 (0.02–5.00)
N00–N99: Diseases of the genitourinary system 8 0.03 1 0.01 2.43 (0.30–19.57)
V01–Y98: External causes of morbidity and mortality 9 0.04 3 0.03 1.10 (0.29–4.12 )
&Number of cases per 100 person years.
doi:10.1371/journal.pone.0028157.t005
Figure 1. Smoothed crude RR of death over duration of
treatment (years) in rosiglitazone users compared to pioglita-
zone users. RR: relative rate.
doi:10.1371/journal.pone.0028157.g001
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challenges in comparing between different classes of diabetes
medication, our study could not evaluate whether the findings are
explained by excess toxicity or by lesser benefit with rosiglitazone.
As an example, pioglitazone is well recognised to cause heart
failure and the decreased RR of heart failure with pioglitazone
may only indicate that pioglitazone is less toxic than rosiglitazone.
The results of this study are consistent with those reported by
Graham and collaegues using US Medicare data [31], although
the follow-up in the present study was considerably longer. Also,
we did not censor at a non-endpoint hospitalisation, as this could
lead to differential loss to follow-up. A study by Wertz, that applied
propensity matching to US claims data from insured employees,
did not find any differences in the risk of death, MI and heart
failure between rosiglitazone and pioglitazone [30]. Although this
study appeared to be well conducted, the data concerned a
restricted population with rates of death and MI lower than in the
present study. Also, no results were provided without propensity
score matching, which is a complex statistical technique. A recent
meta-analysis of observational studies found a RR of mortality for
rosiglitazone which were comparable to the present study,
although it did report a small increased RR for myocardial
infarction [37]. This meta-analysis did not adjust for data quality
and consisted of pooling of studies with varying designs and study
populations.
There is only indirect evidence from RCT comparing
rosiglitazone and pioglitazone, as the large RCTs did not directly
compare these drugs. But the RCTs do suggest differential effects.
The RECORD study (comparing rosiglitazone with metformin or
sulphonylurea to metformin plus sulphonylurea) found that the
rate of cardiovascular death, MI and stroke was statistically
comparable between the groups [38]. In contrast, the PROactive
study found that this outcome was reduced with pioglitazone [39].
Similarly, the FDA meta-analysis found a trend for increased risks
with rosiglitazone and decreased risks for pioglitazone (RRs of
2.14 and 0.54, respectively; P-values.0.05) [4]. The RRs for heart
failure risks were also reported to be nominally higher with
rosiglitazone than with pioglitazone [5]. These meta-analyses,
lumping a set of heterogeneous studies, do not provide definitive
evidence that rosiglitazone is inferior to pioglitazone. Observa-
tional studies, like the present one, are also limited by the potential
for bias [39]. But despite the limitations of the present evidence
base on the safety of rosiglitazone [40], an important consideration
has been that there was limited evidence of a benefit of
rosiglitazone on major clinical outcomes; the largest RCT
(RECORD) did not show any beneficial effects of rosiglitazone
[39]. The excess risks of cardiovascular outcomes in younger
patients (under 65 years) was found to be small with rosiglitazone
in this present study. Clearly, this finding of minimal adverse
effects in younger patients needs be balanced by the lack of
evidence of any beneficial effect of rosiglitazone in this group of
patients.
There are significant challenges in interpreting the scientific
evidence of the safety of medicines. Registration RCTs typically
include a narrow set of patients recruited in specialised centres
who are followed for a limited period of time. Often, these studies
do not have the power to measure the effects on major clinical
outcomes. Meta-analyses are now often conducted to overcome
this limitation but the statistical lumping of heterogeneous RCTs is
clearly not without limitations. The data from epidemiological
studies often suffer from over-reliance on statistical adjustment and
varying quality in data, design and study execution. Discrepant
results within the same database are indicative of the methodo-
logical challenges in epidemiological research [41]. Also, there is
often incomplete evidence after approval of a medicine about the
targeting of the treatment and who should receive it. Thus, there is
a major need to expand our toolbox for obtaining evidence on the
effects of medicines. One option could be large simple RCTs
conducted within a research database, allowing the clinician to
randomise between treatments and then following for outcomes
using the routine electronic health records.
Table 6. Cumulative incidence (%) of outcomes (in GPRD) over one and three years in current rosiglitazone and pioglitazone users.
Year 1 Year 3
Outcome Strata Rosiglitazone Pioglitazone
Excess
risk Rosiglitazone Pioglitazone
Excess
risk
Death All 1.85 (1.65–2.06) 1.48 (1.25–1.76) 0.36 5.80 (5.37–6.27) 4.46 (3.89–5.11) 1.35
Age 40–49 0.21 (0.08–0.57) 0.12 (0.02–0.85) 0.09 0.82 (0.44–1.50) 0.56 (0.21–1.50) 0.25
50–64 0.55 (0.40–0.75) 0.38 (0.23–0.64) 0.17 2.33 (1.91–2.84) 2.00 (1.44–2.76) 0.33
65–74 1.77 (1.44–2.17) 1.67 (1.24–2.25) 0.09 6.15 (5.35–7.06) 4.19 (3.26–5.38) 1.96
75–84 5.00 (4.20–5.95) 4.44 (3.43–5.74) 0.56 14.67 (12.95–16.59) 11.72 (9.46–14.48) 2.95
85+ 15.87 (12.54–19.99) 9.27 (5.83–14.57) 6.6 38.90 (32.34–46.26) 31.81 (22.41–43.89) 7.09
Sex female 1.97 (1.68–2.32) 1.71 (1.33–2.19) 0.26 6.46 (5.76–7.24) 5.39 (4.44–6.55) 1.07
male 1.75 (1.51–2.03) 1.33 (1.05–1.68) 0.42 5.33 (4.79–5.93) 3.83 (3.17–4.63) 1.5
Death, ACS, stroke,
heart failure
All 3.10 (2.83–3.39) 2.81 (2.46–3.21) 0.29 8.85 (8.28–9.45) 7.67 (6.88–8.55) 1.18
Age 40–49 0.70 (0.42–1.17) 0.91 (0.48–1.73) 20.21 1.69 (1.12–2.54) 1.87 (1.12–3.12) 20.18
50–64 1.40 (1.14–1.72) 1.73 (1.34–2.23) 20.32 4.67 (4.05–5.39) 5.29 (4.32–6.47) 20.62
65–74 3.87 (3.32–4.51) 2.81 (2.19–3.61) 1.06 10.91 (9.78–12.17) 8.24 (6.76–10.02) 2.68
75–84 7.42 (6.29–8.75) 6.86 (5.41–8.67) 0.57 20.64 (18.38–23.14) 16.43 (13.46–19.98) 4.21
85+ 19.91 (15.56–25.27) 16.25 (10.83–24.00) 3.66 45.53 (38.34–53.39) 36.60 (26.30–49.36) 8.93
Sex female 3.06 (2.67–3.51) 2.48 (2.00–3.08) 0.58 9.25 (8.38–10.20) 7.91 (6.67–9.36) 1.34
male 3.12 (2.76–3.52) 3.04 (2.57–3.60) 0.07 8.54 (7.81–9.34) 7.50 (6.51–8.64) 1.04
doi:10.1371/journal.pone.0028157.t006
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There are various limitations to this study. Information on
confounders and underlying disease severity was limited in this
study. Furthermore, our analyses provide only simplistic repre-
sentations of the actual exposures to diabetes medications. Drug
exposure in actual clinical practice often varies greatly, with many
different drug combinations being used and patients switching
over time between drugs and patients being non-compliant to
treatment instructions. We did not evaluate this complexity in
exposure and also relied on information of prescriptions rather
than actual use.
In conclusion, the findings in this study support the presence of
unmeasured confounding in the comparisons of cardiovascular
outcomes between different classes of diabetes medications due to
heterogeneity in use (as reflected by the substantive differences in
rates of death during past exposure). Comparable populations used
rosiglitazone and pioglitazone. Higher risks for death (overall and
due to cardiovascular disease) and heart failure were found for
rosiglitazone compared to pioglitazone, with the risks of death
highest shortly after starting treatment and disappearing after
discontinuation of rosiglitazone. These excess risks were largest in
patients aged 65 years or older. This study supports the suspension
of rosiglitazone by European regulatory authorities in September
2010.
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